Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alisporivir for hospitalized COVID-19
2020-002295-13Phase 2Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in coronavirus disease 2019 (COVID-19) comparing Alisporivir plus standard of care with Standard of care alone (2 arms). Primary endpoint: Reduction in SARS-CoV-2 viral load at Day 7. Started May 2020; status: completed.
02
Drugs
alisporivir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-002295-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002295-13.